Lineage Cell Therapeutics Inc. — Director's Dealing 2017

Jul 6, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOTIME INC (BTX)
CIK: 0000876343
Period of Report: 2017-07-01

Reporting Person: SCHLACHET DAVID (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-07-01	Option to Purchase Common Shares	$3.15	A	20000	Acquired	2022-06-30	Common Shares (20000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Shares, no par value	32050	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to Purchase Common Shares	$2.72	2021-06-30	Common Shares (20000)	20000	Direct
Option to Purchase Common Shares	$3.57	2020-06-30	Common Shares (20000)	20000	Direct
Option to Purchase Common Shares	$3.11	2019-06-30	Common Shares (20000)	20000	Direct
Option to Purchase Common Shares	$2.86	2019-04-10	Common Shares (20000)	20000	Direct

Footnotes

F1: All shares are owned by Schlachet Management Ltd., a privately held company of which Mr. Schlachet is the sole shareholder, chief executive officer, and director.

F2: Will become exercisable in four equal quarterly installments after the date of grant on July 1, 2017 based upon continued service on the board of directors.

F3: Became exercisable in four equal quarterly installments after the date of grant on July 1, 2016.

F4: Became exercisable in four equal quarterly installments after the date of grant on July 1, 2015.

F5: Became exercisable in four equal quarterly installments after the date of grant on July 1, 2014.

F6: Became exercisable in four equal quarterly installments after the date of grant on April 11, 2014.